AIM ImmunoTech Announces FDA Clearance of IND Application
Company expects to commence patient enrollment and dosing in Q1 2023...
Source: globenewswire.com
Page 12 - Thomask Equels News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Thomask Equels. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Thomask Equels Today - Breaking & Trending Today
AIM ImmunoTech to Present at the Virtual Investor Long
Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leaders Dr. Charles Lapp of...
Source: globenewswire.com
AIM ImmunoTech to Present at the Virtual Investor Long COVID Event
21.09.2022 - Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leaders Dr. Charles Lapp of Hunter-Hopkins Center and Dr. Daniel Peterson of Sierra Internal Medicine on Wednesday, September 28th at ...
Source: wallstreet-online.de
AIM ImmunoTech Announces Commencement of Phase 2 Study of
Company receives IRB approval of study protocol Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after...
Source: globenewswire.com
AIM ImmunoTech Inc.: AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen for the Treatment of Pancreatic Cancer
Company receives IRB approval of study protocol Ampligen (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with locally
Source: finanznachrichten.de